Comparative Pharmacology
Head-to-head clinical analysis: LAROTID versus PIPERACILLIN AND TAZOBACTAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAROTID versus PIPERACILLIN AND TAZOBACTAM.
LAROTID vs PIPERACILLIN AND TAZOBACTAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Larotrectinib is a selective inhibitor of tropomyosin receptor kinase (TRK) A, B, and C. It inhibits TRK kinase activity by binding to the ATP-binding site, leading to inhibition of downstream signaling pathways, which results in reduced cell proliferation and tumor growth in tumors with NTRK gene fusions.
Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), while tazobactam is a beta-lactamase inhibitor that protects piperacillin from degradation by beta-lactamases.
Larotrectinib 100 mg orally twice daily, with or without food, for adult patients.
3.375 g (piperacillin 3 g + tazobactam 0.375 g) IV every 6 hours, or 4.5 g (piperacillin 4 g + tazobactam 0.5 g) IV every 8 hours for nosocomial pneumonia.
None Documented
None Documented
30 minutes; prolonged in renal impairment (up to 20 hours in anuria).
Piperacillin ~0.7–1.2 h, tazobactam ~0.7–1.5 h; prolonged in renal impairment (piperacillin up to 3.3 h, tazobactam up to 5.6 h in severe impairment).
Renal: 70-80% unchanged by glomerular filtration and tubular secretion; Biliary/Fecal: <10% as inactive metabolites.
Primarily renal: piperacillin ~68% unchanged, tazobactam ~80% unchanged; biliary excretion <10%; fecal <1%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic / Beta-Lactamase Inhibitor Combination